2016-03-07T00:00:00.000-05:00
United States,-0.297745
Abbreviated New Drug,-0.297745
price target range,-0.376441
Buy rating,0.516515
complete response letter,-0.549263
Underperform rating,-0.376441
Paragraph IV Notice,-0.297745
specialty pharmaceutical company,-0.483252
Notice Letter,-0.297745
price target,0.0846184
generic space,-0.572072
teva,0.459482
partner Celgene,0.209129
Q4 results,-0.277317
consumer health business,-0.483252
Outperform rating,0.529918
Leerink analyst Jason,-0.346477
generic portfolio deal,-0.511015
generic Epipen application,-0.549263
analyst Jami Rubin,-0.508562
development strategy,0.416694
pre-dialysis CKD,0.416694
blockbuster Xifaxan drug,0.389046
Allergan,0.371902
Teva shares,0.529918
analyst Jason Gerberry,-0.346477
generic version,-0.328437
Citi analyst Robyn,0.46106
Allergan shares,0.571971
